Ariad Pharmaceuticals Inc fka ARIA

[iandy]

Has 113 been tested long enough in humans to reveal any potential for the issues that now have required the label modification for xalkori?

In a word - no.
It is too soon to know if the liver toxicity is drug specific or class specific.
113 has the potential to deliver a more favorable side effect profile.
As bell mentioned, They haven't seen any significant safety issues so far.

I was finally able to access the call today.

Regarding pona:
They said that their impression from the pona meeting with the FDA was the data can really become the basis for approval.

I agree with Harvey's closing remarks.
It was a great call with great questions.